6533b7ddfe1ef96bd12749ed
RESEARCH PRODUCT
Epidemiological, clinical and genomic snapshot of the first 100 B.1.1.7 SARS-CoV-2 cases in Madrid
Darío García De ViedmaPilar Catalán PharmacyAgustín EstévezPedro J Sola CampoyLaura Pérez-lagoJulia Suárez-gonzálezMariana G. LópezPatricia MuñozIñaki ComasFernando González-candelasVíctor Manuel De La Cueva TechnicianLuis AlcaláMarta Herranz TecnichianSergio Buenestado-serranosubject
AdultMale2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)AdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030231 tropical medicine03 medical and health sciencesYoung Adult0302 clinical medicineResearch LetterMedicineHumans030212 general & internal medicineUKChildB.1.1.7travelAgedAged 80 and overTravelbusiness.industrySARS-CoV-2InfantCOVID-19General MedicineGenomicsMiddle AgedSpainChild PreschoolFemalebusinessHumanitiesAcademicSubjects/MED00295description
A new SARS-CoV-2 variant, B.1.1.7, emerged in September in the UK, and is responsible for 76.6% of COVID-19 cases.1 This variant has also been reported in another 45 countries, 17 of them European.2,3 B.1.1.7 is considered to have higher transmissibility.4 It carries an unusually high number of specific mutations/deletions, 18, mostly non-synonymous and eight concentrate in the S gene,5 including several which might have relevant functional roles. The 69/70 deletion may be associated to immune response evasion6 and the N501Y substitution increases the affinity to the ACE2 receptor.7 These findings have raised the alarm of having to face a new variant with the potential to accelerate the spread of the pandemic. A recent report finds a realistic possibility that B.1.1.7 is associated with an increased risk of death.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-01 |